X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-grants-full-approval-pfizers-cervical-cancer-drug-2024-04-29/
https://www.globenewswire.com/news-release/2024/04/29/2871730/0/en/TIVDAK-tisotumab-vedotin-tftv-Receives-U-S-FDA-Approval-to-Treat-Recurrent-or-Metastatic-Cervical-Cancer.html
https://www.globenewswire.com//news-release/2024/01/09/2806100/0/en/TIVDAK-tisotumab-vedotin-tftv-Supplemental-Biologics-License-Application-Accepted-for-Priority-Review-by-U-S-Food-and-Drug-Administration-for-Patients-with-Recurrent-or-Metastatic-.html
https://www.globenewswire.com//news-release/2023/10/22/2764331/0/en/TIVDAK-tisotumab-vedotin-tftv-Significantly-Prolonged-Overall-Survival-in-Patients-with-Recurrent-or-Metastatic-Cervical-Cancer-Compared-with-Chemotherapy-in-Global-Phase-3-innovaT.html
https://www.globenewswire.com//news-release/2023/09/04/2736906/0/en/Genmab-and-Seagen-Announce-That-TIVDAK-tisotumab-vedotin-tftv-Met-its-Primary-Endpoint-of-Improved-Overall-Survival-in-Patients-with-Recurrent-or-Metastatic-Cervical-Cancer-Compare.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761208
https://www.fiercebiotech.com/biotech/genmab-seattle-genetics-eye-fda-filing-after-seeing-cancer-data
https://investor.seattlegenetics.com/press-releases/news-details/2020/Seattle-Genetics-Announces-Positive-Topline-Results-from-Phase-2-Clinical-Trial-of-Tisotumab-Vedotin-in-Recurrent-or-Metastatic-Cervical-Cancer/default.aspx
https://ir.genmab.com/news-releases/news-release-details/genmab-announces-very-favorable-topline-results-phase-2-clinical
Market Place
Share 
